Top brokerages upgrade ride-hail and biopharma stocks while adjusting ratings on defense and chemical sectors amid shifting market dynamics.
Rothschild & Co Redburn upgraded Lyft (LYFT) to Buy from Neutral, raising its price target to $22 from $17. The firm cited autonomous vehicle adoption as a catalyst for expanding ride-hailing markets, calling current share levels an attractive entry point.
Morgan Stanley upgraded Charles River (CRL) to Overweight with a $220 target, up from $185, as biopharma funding trends support preclinical demand. Wells Fargo also lifted Carter’s (CRI) to Equal Weight, targeting $42, citing leadership improvements and direct-to-consumer growth.
Mizuho adjusted Huntsman (HUN) to Neutral following its merger with Olin (OLN), aligning its rating with Olin’s Neutral stance. BTIG upgraded MFA Financial (MFA) to Buy with a $10.50 target, reflecting sector-specific optimism.